Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [3] - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in clinical development [3] - The second product candidate, LTI-01, has completed Phase 1b and Phase 2a trials for loculated pleural effusions and has received Orphan Drug Designation in both the U.S. and E.U. [3] Upcoming Events - Chief Scientific Officer Cory Hogaboam will present at the IPF Summit 2025 on August 19-21, 2025, discussing the role of immune cells and inflammation in idiopathic pulmonary fibrosis (IPF) [2] - CEO Brian Windsor will present on August 21, focusing on innovative clinical trial design and lessons learned from the LTI-03 trial [2] Research and Development Focus - The presentations will cover the modulation of lung-resident macrophages and the potential of Caveolin-scaffolding domain (CSD) peptides in targeting multiple drivers of fibrosis [5] - Rein's Phase 2 trial of LTI-03 aims to enroll up to 120 patients, assessing safety, tolerability, and lung function as key outcomes [5] - The company is strategizing around patient recruitment and trial design to ensure relevance in a rapidly evolving treatment landscape [5]

Core Viewpoint - Flexible Solutions International, Inc. reported its financial results for the second quarter of 2025, highlighting an increase in sales and net income despite facing challenges such as tariff increases and soft sales [2][3]. Financial Performance - Sales for Q2 2025 were $11,367,132, representing an increase of approximately 8% compared to $10,528,739 in Q2 2024 [7]. - Net income for Q2 2025 was $2,028,912, or $0.16 per basic share, compared to $1,289,796, or $0.10 per basic share in Q2 2024 [7]. - The increase in earnings was largely attributed to research and development services sales, with some related expenses recognized in previous quarters [7]. Operational Developments - The NanoChem division and ENP subsidiary remain the primary sources of revenue and cash flow for the company [4]. - The company is transitioning its legacy production to Panama for international customers while expanding its food-grade business in Illinois [3][4]. - New opportunities are emerging in various sectors, including detergent, water treatment, oil field extraction, and food and nutrition supplement manufacturing [4]. Cash Flow Analysis - For the six months ended June 30, 2025, the company reported an operating cash flow of $4,253,875, or $0.34 per basic share, compared to $3,853,907, or $0.31 per basic share in the same period of 2024 [7][9]. - The basic weighted average shares used in computing earnings per share were 12,647,532 for Q2 2025, up from 12,450,532 in Q2 2024 [7].

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Veea Inc. (NASDAQ: VEEA) (“Veea” or the “Company”), a leader in intelligent edge infrastructure, announced the closing of its public offering of an aggregate of 9,189,096 shares of common stock and warrants to purchase up to 9,189,096 shares of common stock at a combined offering price of $1.00 per share and accompanying warrant (the “Offering”). The Company received aggregate cash gross proceeds of approximately $6.0 million, before deducting placement agent fees ...

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector. With over 300 virtual specialists in over 30 specialties, supporting both GP-referred appointments as well as providing virtual ...

Financial Performance - Daily Journal Corporation reported consolidated revenues of $59,286,000 for the nine months ended June 30, 2025, an increase of $9,228,000 from $50,058,000 in the prior year period, driven by higher license and maintenance fees, consulting fees, and public service fees from Journal Technologies, as well as increased advertising revenues from the Traditional Business [1] - The Traditional Business' pretax income decreased by $1,364,000 to $237,000, primarily due to increased expenses of $2,290,000, despite a revenue increase of $926,000 [2] - Journal Technologies' pretax income increased by $3,947,000 to $4,692,000, attributed to increased operating revenues of $8,302,000, partially offset by increased operating expenses of $4,355,000 [2] - Consolidated pretax income was $94,396,000, compared to $68,195,000 in the prior fiscal year period, with consolidated net income of $69,986,000 ($50.81 per share) for the nine months ended June 30, 2025, up from $51,385,000 ($37.32 per share) in the prior year [5] Marketable Securities - As of June 30, 2025, the Company held marketable securities valued at $443,011,000, including net pretax unrealized gains of $303,917,000, with a deferred tax liability of $79,260,000 for estimated income taxes due upon the sale of appreciated securities [3] Non-Operating Income - The Company's non-operating income, net of expenses, increased by $23,618,000 to $89,467,000, primarily due to net unrealized gains on marketable securities of $84,320,000, compared to realized and unrealized gains of $62,472,000 in the prior fiscal year [4] - There was also an increase in dividends and interest income of $301,000 to $6,158,000 from $5,857,000 [4] Tax Provision - For the nine months ended June 30, 2025, the Company recorded an income tax provision of $24,410,000 on the pretax income of $94,396,000, resulting in an overall effective tax rate of 25.9% [6]

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (“Emerita” or the “Company”) (TSXV:EMO) (OTCQB:EMOTF) (FSE:LLJA) is pleased to announce that due to investor demand, the previously announced brokered offering of up to 23,809,500 units of the Company (the “Initial Offering”), is fully subscribed and that the Compan ...

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. “During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clini ...

Core Insights - Invivyd, Inc. is entering a transformative phase with a focus on VYD2311 as a promising alternative to COVID-19 vaccination, supported by recent clinical trial data [2][5][7] - The company reported a significant year-over-year increase in net product revenue for PEMGARDA, reaching $11.8 million in Q2 2025, representing a 413% growth [5][9] - Despite not meeting the near-term profitability target for the first half of 2025, Invivyd remains optimistic about achieving profitability with the upcoming respiratory virus season [5][9] Recent Business Highlights - The company is actively designing clinical and go-to-market strategies for VYD2311, which has shown an attractive safety profile and pharmacokinetics in Phase 1/2 trials [2][5] - Invivyd anticipates identifying a best-in-class RSV candidate in Q3 2025 and a preclinical measles candidate by the end of 2025 [2][5] Clinical & Regulatory Developments - Invivyd has aligned with the U.S. FDA on a rapid pathway to full approval for VYD2311, which aims to protect American adults and adolescents from COVID-19 [5][7] - The VYD2311 candidate demonstrated a 76-day observed half-life for intramuscular administration, indicating potential for long-term protection [5][6] Commercial Execution - PEMGARDA's uptake is increasing among healthcare providers for immunocompromised patients, supported by Invivyd's sales force and expanded field presence [6][10] - The product has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for B-Cell Lymphomas [6] Financial Results - For Q2 2025, Invivyd reported a net loss of $14.7 million, a decrease from $47.2 million in Q2 2024, with a net loss per share of $0.12 [9][28] - Research and development expenses were $9.6 million for the quarter, down from $30.3 million in the same period of 2024, primarily due to reduced clinical trial costs [9][28] Pipeline Expansion - The company is exploring pipeline expansion beyond SARS-CoV-2, including potential targets like RSV and measles [11][19] - Invivyd has formed the SPEAR Study Group to assess monoclonal antibody therapy effects for Long COVID and COVID-19 Post-Vaccination Syndrome [11][19]

Core Viewpoint - Invivyd, Inc. has received guidance from the U.S. FDA on a rapid pathway for Biologics License Application (BLA) approval for its monoclonal antibody candidate VYD2311, aimed at preventing COVID-19, which could provide an alternative to vaccines for the American population [1][2][3] Group 1: FDA Guidance and Clinical Trials - The FDA advised that a single Phase 2/3 randomized, double-blind, placebo-controlled trial could support a BLA submission for VYD2311, focusing on symptomatic COVID-19 events [1][3] - Invivyd plans to study two doses of VYD2311 to evaluate differences in protection levels and safety, aiming to provide more options for COVID-19 protection [2][4] - The primary endpoint for the trial is RT-PCR-confirmed symptomatic COVID-19, with a measurement timepoint expected at 12 weeks, and a potential longer duration of 24 weeks [3][4] Group 2: Product Profile and Market Position - VYD2311 is designed to be a low-dose, intramuscular, scalable, and cost-effective option for adults and adolescents, with potential expansion to pediatric populations [4][5] - The antibody is engineered to neutralize contemporary virus lineages and is based on a common molecular lineage with other successful Invivyd antibodies [2][8] - Invivyd's analysis suggests that VYD2311 may provide robust, long-term protection from symptomatic COVID-19 due to its high potency and long half-life of approximately 76 days [4][5] Group 3: Strategic Importance and Future Plans - The company emphasizes the importance of providing a non-vaccine choice for COVID-19 prevention amidst declining public trust in vaccines [2][3] - Invivyd has quantities of VYD2311 available for clinical supply and potential commercial launch, indicating readiness for market introduction if approved [6][8] - The company aims to finalize a pivotal clinical trial design with the FDA and is committed to advancing innovative solutions for COVID-19 prevention [6][3]

Core Insights - PetVivo Holdings, Inc. reported a significant increase in revenues for the first quarter of fiscal year 2026, with total revenues reaching $298,000, marking a 141% increase compared to the same period last year [5][27][29] - The company is expanding its market presence, particularly in the companion animal sector, and has initiated international sales through a distribution agreement in Mexico [10][11][20] Fiscal Q1 Financial Highlights - Revenues increased to $298,000, a 141% rise year-over-year, driven by product line expansion and increased sales force efforts [5][27] - Gross profit rose 69% to $187,000, with a gross margin of 63% [5][28] - Operating loss decreased by 9% to $1.8 million, attributed to strategic restructuring and cost reduction initiatives [5][29] - Net loss increased 13% to $2.3 million, or $(0.09) per share, due to higher non-cash expenses [5][29] - Cash reserves increased to $3.3 million from $228,000 at the end of the previous quarter, primarily due to financing activities [5][30] - Total liabilities decreased by 39% to $3.1 million, mainly due to lease terminations and modifications of convertible note terms [5][31] Fiscal Q1 Operational Highlights - The company signed a distribution agreement with Eq Especialidades to promote Spryng™ in Mexico, marking its first international market entry [5][20] - A strategic partnership with PiezoBioMembrane aims to develop innovative biomaterials for tissue regeneration [5][24] - Collaboration with Digital Landia focuses on integrating AI technology to enhance veterinary care through real-time analysis of animal behavior [5][17] - Sales and marketing efforts are ramping up for the commercialization of PrecisePRP, a new product for treating osteoarthritis in animals [5][14] - A partnership with Commonwealth Markets integrates Spryng® and PrecisePRP into care protocols for thoroughbred horses [5][21] Industry Outlook - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [5][26] - The veterinary healthcare market in Mexico is expected to grow at a compounded annual growth rate of 11% to reach $2.4 billion by 2031 [10]